Tracking the evolution of cancer cell populations through the mathematical lens of phenotypestructured equations
 Tommaso Lorenzi^{1}Email authorView ORCID ID profile,
 Rebecca H. Chisholm^{2} and
 Jean Clairambault^{3, 4}
Received: 11 April 2016
Accepted: 20 July 2016
Published: 23 August 2016
Abstract
Background
A thorough understanding of the ecological and evolutionary mechanisms that drive the phenotypic evolution of neoplastic cells is a timely and key challenge for the cancer research community. In this respect, mathematical modelling can complement experimental cancer research by offering alternative means of understanding the results of in vitro and in vivo experiments, and by allowing for a quick and easy exploration of a variety of biological scenarios through in silico studies.
Results
To elucidate the roles of phenotypic plasticity and selection pressures in tumour relapse, we present here a phenotypestructured model of evolutionary dynamics in a cancer cell population which is exposed to the action of a cytotoxic drug. The analytical tractability of our model allows us to investigate how the phenotype distribution, the level of phenotypic heterogeneity, and the size of the cell population are shaped by the strength of natural selection, the rate of random epimutations, the intensity of the competition for limited resources between cells, and the drug dose in use.
Conclusions
Our analytical results clarify the conditions for the successful adaptation of cancer cells faced with environmental changes. Furthermore, the results of our analyses demonstrate that the same cell population exposed to different concentrations of the same cytotoxic drug can take different evolutionary trajectories, which culminate in the selection of phenotypic variants characterised by different levels of drug tolerance. This suggests that the response of cancer cells to cytotoxic agents is more complex than a simple binary outcome, i.e., extinction of sensitive cells and selection of highly resistant cells. Also, our mathematical results formalise the idea that the use of cytotoxic agents at high doses can act as a doubleedged sword by promoting the outgrowth of drug resistant cellular clones. Overall, our theoretical work offers a formal basis for the development of anticancer therapeutic protocols that go beyond the ‘maximumtolerateddose paradigm’, as they may be more effective than traditional protocols at keeping the size of cancer cell populations under control while avoiding the expansion of drug tolerant clones.
Reviewers
This article was reviewed by Angela Pisco, Sébastien Benzekry and Heiko Enderling.
Keywords
Background
A growing body of evidence indicates that cancer progression at the cellular level is, in essence, an evolutionary process [1–6]. During cancer progression, novel phenotypic variants emerge via heritable changes in gene expression. Subsequently, phenotypic variants are subject to natural selection – they survive, reproduce, and die – under the action of the tumour microenvironment and anticancer agents. The scenario is further complicated by celltocell variability in gene expression, which gives rise to phenotypic differences between cancer cells of the same population. This phenotypic heterogeneity is a dynamic source of therapeutic resistance that needs to be accounted for when investigating effective anticancer therapeutic protocols [7].
Novel phenotypic variants in cancer cell populations originate mainly from mutations (i.e., genetic modifications). However, novel phenotypic variants can also emerge due to epimutations (i.e., heritable changes in gene expression that leave the sequence of bases in the DNA unaltered) [8–12]. For instance, recent experiments using fluorescentactivated cell sorting have demonstrated that nongenetic instability mediated by fluctuating protein levels allows cancer cells to reversibly transition between different phenotypic states [13–15]. Such nongenetic source of phenotypic variability has been increasingly recognised as integral to the development of resistance to cytotoxic agents in cancer cell populations [16, 17].
Identifying the ecological and evolutionary mechanisms that drive the phenotypic evolution of neoplastic cell populations is, therefore, a timely and key challenge for the cancer research community. In this regard, mathematical modelling provides additional tools in the fight against cancer, and many biologists and clinicians are now looking for a mathematical approach to complement their research [18–27]. Among others, models arising from mathematical ecology enable falsification of biological hypotheses concerning the principles that underpin the dynamics of neoplastic cell populations, and extrapolation beyond scenarios analysed by means of in vitro and in vivo experiments [28].
During the last fifty years, partial differential equations (PDEs) for populations structured by physiological traits have been extensively used to achieve a better understanding of a wide range of ecological phenomena [29, 30]. These equations describe population dynamics in terms of the evolution of population densities across phenotypic spaces, and can be derived from individualbased (IB) models through suitable asymptotic limits [31–33]. However, unlike IB models, which can be explored mainly through numerical simulations only, PDEs for populations structured by physiological traits make it possible to integrate numerical simulations with rigorous analysis, in order to achieve more robust biological conclusions [34].
In particular, we have recently shown that phenotypestructured PDEs constitute a convenient apparatus to study in silico the dynamics of cancer cell populations. In more detail, we formulated a PDE model for the coevolution of a population of healthy cells and a population of cancer cells structured by the level of resistance to a cytotoxic drug [35]. Further, we extended this model to consider cell populations structured also by a spatial variable [36]. Most recently, we presented a PDE model of phenotypic evolution in a cancer cell population structured by the expression levels of two phenotypic traits, survival potential and proliferation potential [37]. Overall, the results of our analyses and numerical simulations provide a new perspective on the inherent risks of interventional chemotherapy in cancer patients by showing how the adaption of even nongenetically unstable cell populations exposed to antiproliferative drugs can be acted upon by selective forces, which drive the outgrowth of drug resistant cell clones.
To investigate the roles of phenotype plasticity and selection pressures in tumour relapse, here we propose a phenotypestructured PDE model of evolutionary dynamics in a cancer cell population which is exposed to the action of a cytotoxic drug within an in vitro culture system. Our model is informed by a previous conceptual model [38] and focuses on a cancer cell population structured by the expression level of a gene which is linked to both the cellular levels of cytotoxicdrug resistance and proliferative potential – such as ALDH1, CD44, CD117 or MDR1 [39, 40]. We characterise the phenotypic state of each cell by means of a continuous variable related to the level of expression of this gene, and we allow the cell phenotypic state to change in time due to nongenetic instability, which is mediated by random epimutation events. The inclusion of a dynamic continuous population structure and its plasticity makes PDE models a natural framework to study, in silico, the phenotypic evolution of cancer cells. Note that, in the model presented here, nongenetic instability is purely random and represented by a constant rate multiplying a diffusion operator. In more sophisticated models involving metabolismdependent epigenetic dynamics, as those advocated in [41], this constant would be replaced by a suitable function to incorporate the effects of the cell load in histone demethylases, DNA methyltransferases, or other epigenetic enzymes, together with their substrates and coenzymes.
Exploiting the analytical tractability of our model, we dissect the relative contributions of random epimutations, natural selection and competition for resources as drivers of adaptation in cancer cell populations that evolve under the action of cytotoxic drugs. This analytical work builds on recent advances in the study of nonlocal PDEs that arise in models of population dynamics [33, 42, 43], which enable us to explore the parameter space of our model completely. To illustrate analytical results through numerical simulations, we calibrate our model by means of existing data from in vitro experiments on the phenotypic evolution of HL60 leukemic cells exposed to vincristine [14]. Nonetheless, the results of our analyses are qualitatively robust across a wide range of parameter values. This makes the conclusions presented in our current work applicable to a broad spectrum of cancer cell lines evolving under the action of different cytotoxic agents.
Our main findings elucidate how the phenotype distribution, the level of phenotypic heterogeneity and the size of cancer cell populations exposed to cytotoxic drugs are shaped by the strength of natural selection, the rate of random epimutations, the intensity of the competition for limited resources between cells, and the drug dose in use. Moreover, we are able to obtain exact conditions for the successful adaptation of cancer cells, and we find that whilst phenotypic plasticity may facilitate adaptation in neoplastic cell populations exposed to cytotoxic drugs, frequent fluctuations in protein levels can also contribute to extinction in the presence of high drug concentrations. Finally, our mathematical results provide a ‘proof of concept’ of the hypothesis that the use of cytotoxic agents at high doses is a doubleedged sword in the fight against cancer, and offer a formal basis for the development of therapeutic protocols which effectively exploit evolutionary mechanisms to improve the efficacy of cytotoxic therapy.
Methods
In this mathematical framework, the function σ ^{2}(t) provides a measure of the level of intrapopulation heterogeneity at time t. Finally, we introduce the function c(t)≥0 to model the concentration of cytotoxic drug at time t. Throughout the paper, we will mainly focus on the case of continuous drug infusion, and we will use the parameter C>0 to model the constant concentration of cytotoxic drug inside the system.
PDE model
In the above equation, Ω is a compact subset of \(\mathbb {R}\). Eq. (3) relies on the assumptions and the modelling strategies presented in the following subsections.
Mathematical modelling of nongenetic instability
To reduce biological complexity to its essence, we make the prima facie assumption that random epimutations yield infinitesimally small phenotypic modifications [44, 45]. Therefore, we model the effects of nongenetic instability through a diffusion operator. The diffusion coefficient β>0 in Eq. (3) stands for the rate of epimutation of cancer cells, which is assumed to be constant, as mentioned earlier.
Mathematical modelling of natural selection
In the above definitions, the parameter γ>0 corresponds to the maximum fitness of cancer cells, and the nonlinear selection gradient η>0 provides a measure of the strength of natural selection in the absence of xenobiotic agents.
Setup of numerical simulations and model parametrisation
We numerically solve the mathematical problem defined by completing Eq. (3) with boundary conditions (4) and the following initial condition
where b and L are positive numbers, a _{ i }>0 are uniformly distributed random numbers between 0 and 1, x _{ i } are uniformly distributed random numbers between −L and L, and K>0 is the carrying capacity of the population. The above definition represents an initial population composed of different cellular clones labelled by the index i=1,…,N. To perform numerical simulations, we set N=20.
Numerical computations are performed in MATLAB. We select a uniform discretisation consisting of 1200 points on the interval [−2L,2L] with L=2 as the computational domain. The method for calculating numerical solutions is based on a time splitting scheme between the conservative part and the reaction term [46]. As for the conservative part, we approximate the diffusion term through a threepoint explicit scheme. On the other hand, we use an implicitexplicit finite difference scheme for the reaction term [35]. For all simulations, we set the time step d t=10^{−4}, in order to ensure the stability of the numerical scheme.
Values of the parameters used to perform numerical simulations
Parameter  Biological meaning  Value 

γ  Maximum fitness  0.66 per day 
η  Selection gradient  0.132 per day 
d  Rate of death due to intrapopulation competition  0.66×10^{−8} per day 
β  Rate of epimutation  0.01 per day 
Results and discussion
Cell dynamics in the absence of xenobiotic agents
As mentioned earlier, in the framework of our model, the total number of cells ρ(t), the average phenotypic state μ(t) and the level of intrapopulation heterogeneity σ ^{2}(t) are computed according to Eqs. (1)–(2). Then, in the absence of xenobiotic agents (i.e., when c(·)=0), a complete characterisation of the cancer cell population at equilibrium is provided by the following theorem:
Theorem 1
 (i)if γ−(β η)^{1/2}≤0,$$ \rho(t) \rightarrow 0, \qquad \text{as }\, t \rightarrow \infty; $$(9)
 (ii)if γ−(β η)^{1/2}>0,$$ \rho(t) \rightarrow \overline{\rho} = \frac{1}{d}\left[ \gamma(\beta\eta)^{1/2} \right], \qquad \text{as }\, t \rightarrow \infty $$(10)and$$ \overline{n}(x) = \overline{\rho} \; \frac{{(\eta/\beta)^{1/4}}}{(2\pi)^{1/2}} \exp\left[\frac{1}{2}\left(\frac{\eta}{\beta}\right)^{1/2} x^{2}\right], $$(11)so that$$ \mu(t) \rightarrow \overline{\mu} = 0~~\text{and} \quad \sigma^{2}(t) \rightarrow \overline{\sigma}^{2} = \sqrt{\frac{\beta}{\eta}},~~~\text{as }\, t \rightarrow \infty. $$(12)
The results established by Theorem 1 are discussed, as points R1  R4 below, and illustrated by means of numerical simulations in the following subsections. The proof is detailed in Appendix 1 – to which we refer the mathematically inclined reader – and it follows from a general analysis that we have presented in two recent papers [33, 42].
R1. Higher rates of random epimutations can drive the cancer cell population to extinction under strong selective pressures
Point (i) of Theorem 1 shows that the total number of cells ρ(t) converges to zero when the value of the product between the epimutation rate β and the nonlinear selection gradient η exceeds the square of the maximum fitness γ. Hence, in the presence of large selection gradients, high rates of random epimutations increase the probability of ultimate extinction. This suggests that frequent random epimutations can drive cancer cell populations to extinction under strong selective pressures.
R2. The population evolves to be mainly composed of highly proliferative cells
Point (ii) of Theorem 1 demonstrates that, for any initial population density n(x,0), the equilibrium phenotype distribution \(\overline {n}(x)\) is unimodal with the average phenotypic state \(\overline {\mu }\) being at the maximum point of the distribution x=0, and the total number of cells converges to the stable positive value \(\overline {\rho }\). This holds true for all parameter settings, on the condition that the maximum fitness γ, the nonlinear selection gradient η and the rate of random epimutations β satisfy the relation γ−(β η)^{1/2}>0.
R3. The number of cells and the level of intrapopulation heterogeneity at equilibrium depend on the rate of random epimutations and on the strength of natural selection
R4. The population size at equilibrium depends also on the maximum fitness and on the rate of cell death due to intrapopulation competition
Cell dynamics under the action of cytotoxic drug
Although the phenotype distribution and the number of cells at equilibrium, as well as the time required for the population to recover, vary depending on the choice of the drug dose, the dynamics of the population density and the total number of cells remain qualitatively similar to those shown in Fig. 4. A complete characterisation of the cancer cell population at equilibrium is provided by the following theorem:
Theorem 2
 (i)if γ _{ c }−(β η _{ c })^{1/2}≤0,$$ \rho(t) \rightarrow 0, \qquad \text{as }\, t \rightarrow \infty; $$(14)
 (ii)if γ _{ c }−(β η _{ c })^{1/2}>0,$$ \rho(t) \rightarrow \overline{\rho}_{c} = \frac{1}{d}\left[\gamma_{c}(\beta\eta_{c})^{1/2} \right], \qquad \text{as }\, t \rightarrow \infty $$(15)and$$ \overline{n}_{c}(x) = \overline{\rho}_{c} \; \frac{{(\eta_{c}/\beta)^{1/4}}}{(2\pi)^{1/2}} \exp\left\{\frac{1}{2}\left(\frac{\eta_{c}}{\beta}\right)^{1/2} \left[x\overline{x}_{c}\right]^{2}\right\}, $$(16)with$$ \overline{x}_{c} := \frac{C}{\eta+C}, $$(17)so that$${} \mu(t) \rightarrow \overline{\mu}_{c} = \overline{x}_{c}~~\text{and} \quad \sigma^{2}(t) \rightarrow \overline{\sigma}^{2}_{c} = \sqrt{\frac{\beta}{\eta_{c}}},~~\text{as }\, t \rightarrow \infty. $$(18)
As explained in Appendix 2, the proof of Theorem 2 follows the method of proof of Theorem 1. Here we proceed by discussing, as points R5  R8 below, the pieces of biological information which are conveyed by the above mathematical results. Furthermore, in order to extend the analytical results established by Theorem 2, we perform numerical simulations letting the drug concentration vary over time. The obtained results are discussed as points R9 and R10 below.
R5. Higher rates of random epimutations can drive the population to extinction in the presence of high drug doses
Point (i) of Theorem 2 shows that the total number of cells ρ(t) converges to zero when the value of the product between the rate of random epimutations β and the sum of the nonlinear selection gradient η and the drug concentration C is larger than the square of the maximum fitness γ. This supports the idea that higher rates of random epimutations increase the chance that cancer cell populations go extinct when exposed to sufficiently high concentrations of cytotoxic agents.
R6. Higher drug doses correspond to lower cell numbers
R7. Higher drug doses promote a selective sweep towards more resistant phenotypic variants
The results established by Point (ii) of Theorem 2 indicate that, during cytotoxicdrug treatment, the surviving cells can reside within a spectrum of intermediate phenotypic states – ranging from less drug resistant states to more drug tolerant states – depending on the dose in use. These results indicate that different concentrations of the same cytotoxic drug can lead to the selection of cancer cells in different phenotypic states. In particular, while high doses confer a competitive advantage to highly resistant phenotypic variants, lower concentrations of cytotoxic drugs promote the selection of intermediate levels of cytotoxicdrug resistance and proliferative potential, which may result in an advantageous therapeutic outcome.
R8. The level of intrapopulation heterogeneity decreases as the drug dose increases
R9. The cancer cell population regains cytotoxicdrug sensitivity when drug delivery is discontinued
In order to extend the analytical results established by Theorem 2, we perform numerical simulations letting the drug concentration vary over time [i.e., we consider the case in which the drug concentration is modelled by a function of time c(t)]. In particular, we explore the dynamics of the cancer cell population exposed to a piecewisecontinuous periodic delivery of the cytotoxic drug. As illustrated by the results presented in the Additional file 2, our model predicts the selection of cells in a more resistant phenotypic state in the presence of the cytotoxic drug, whereas selection is reverted in favour of drugsensitive cells when drug delivery is discontinued. Also, the same results clearly show that administering the cytotoxic drug in an alternate fashion leads to the emergence of cycling subpopulations of drugresistant and drugsensitive cells.
R10. Comparing the administration of highdrug doses separated by drugfree periods with the continuous delivery of relatively lowdrug doses
Conclusions
Although technological progress in molecular cell biology has resulted in large amounts of data documenting cancer progression, our understanding of the principles that underpin the development of resistance to anticancer agents and the emergence of phenotypic heterogeneity in neoplastic cell populations is filled with gaps and unresolved questions.
This work is presented with the perspective that mathematical modelling can help to address some of these gaps in our knowledge by capturing, in abstract terms, the crucial assumptions that underlie given hypotheses, and by offering alternative means of understanding experimental results that are currently available. With this perspective, our goal here is to contribute to a systematic identification of the way in which the phenotypic distribution, the level of intrapopulation heterogeneity and the size of cancer cell populations depend on the rate of random epimutations, the strength of natural selection, the intensity of the competition for resources, and the stress exerted by cytotoxic agents.
We have presented and analysed a PDE model of adaptive dynamics in a cancer cell population that is structured by the level of expression of a gene which is linked to cytotoxicdrug resistance and proliferative potential. While the parameter values that we have used to perform numerical simulations are derived from leukemia datasets, our analytical results are characterised by broad structural stability under parameter changes, and can accommodate parameter values from any other type of cancer.
The results of our analyses show that more intense nongenetic instability, stronger selection pressures and fierce competition for limited resources bring about cancer cell populations of smaller size. A more subtle question is how phenotypic heterogeneity is maintained or suppressed in cancer cell populations. Our model predicts that higher rates of random epimutations lead to higher phenotypic diversity, whilst intense selection pressures and high doses of cytotoxic drugs can deplete variation in the phenotypic pool of cancer cell populations, thus causing lower levels of intrapopulation heterogeneity. These findings recapitulate the results presented in previous theoretical and experimental studies of phenotypic evolution in neoplastic cell populations exposed to cytotoxic drugs [51–56].
Epigenetic mechanisms are increasingly implicated in the adaptation of neoplastic cells which face environmental changes. However, since epimutation rates are small in comparison to selection gradients, it might be speculated that the direction of evolution in cancer cell populations is determined exclusively by natural selection. On the contrary, our analytical results suggest that, in the presence of high concentrations of cytotoxic agents, frequent fluctuations in the cellular protein levels can trigger a type of ‘epimutational meltdown’ and contribute to extinction in nonfluctuating environments. This effect escalates under harsher environmental conditions (i.e., for lower maximum fitness and higher selection gradients). Since we have derived a simple and general condition that can lead to population extinction – which is embodied by an explicit relation between the proliferation and death rates of cancer cells, the rate of epimutations and the concentration of the cytotoxic drug [vid., point (i) of Theorem 2] – the validity of this argument can be tested in vitro. Because of the striking similarities between populations of cancer cells and microbial populations [57], an experimental setting analogous to that presented in [58] – where the authors made use of isogenic populations of engineered bacteria that randomly transitions between different phenotypic states to study adaptation to artificial environments – may prove to be useful for this purpose.
Here we have found that the same cell population exposed to different concentrations of the same cytotoxic drug can take different evolutionary trajectories, which culminate in the selection of phenotypic variants characterised by different levels of drug tolerance. This supports the notion that the response of cancer cells to cytotoxic agents is more complex than a simple binary outcome, i.e., extinction of sensitive cells and selection of highly resistant cells, and agrees with insights from empirical works that highlight how different phenotypic variants can be selected inside the same solid tumour depending on the local concentrations of cytotoxic agents [59–61]. Also, in agreement with the experimental results presented by Sun et al. [62], our model suggests that cancer cell populations may regain sensitivity to cytotoxic drugs after a ‘drug holiday’.
In current clinical practice, it is common to give the maximum tolerated dose (MTD) of cytotoxic agents at the beginning of a therapy cycle, and then let the patient recover from toxicities. In the last decade, experimental and theoretical efforts have been made to determine the best scheduling of cytotoxic agents in anticancer therapy; unfortunately, there is still no clear answer about optimal administration protocols. Our work demonstrates that higher doses of cytotoxic drugs reduce the size of cancer cell populations at the cost of promoting the selection of more resistant phenotypic variants. Moreover, our analyses support the development of therapeutic approaches that go beyond the ‘MTD paradigm’. For instance, our results provide a theoretical basis for the benefits of metronomic therapy [63–66] – which relies on the continuous delivery of cytotoxic agents at relatively low, minimally toxic doses – and adaptive therapy [67] – which aims at enforcing a stable tumour burden by permitting sensitive cells to suppress highly resistant cells in low drug pressure conditions – as they may be more effective than traditional protocols at keeping the size of cancer cell populations under control while avoiding the expansion of drug tolerant clones.
We conclude with an outlook on possible extensions of the present work. Here, we have assumed that cell proliferation and drug resistance are interconnected. A natural way to extend our study would be to take into account a degree of independence in these processes by incorporating a second phenotypic variable. In this setting, we could also introduce an advection term to explore the effects of environmental stresses (e.g., hypoxia, acidity or starvation) that may induce cells to actively acquire a more stress resistant phenotype. In so doing, we would be in the position to analyse how the interplay between selection, nongenetic instability and stressinduced adaptation governs the emergence of intratumour heterogeneity and the development of drug tolerance inside solid tumours, which is a theme that we began exploring in a previous paper [37].
The present model could also be extended to include the effects of the phenotypic coevolution and spatial interaction between cancer cells and cells of the tumour microenvironment. In fact, the growth and death of neoplastic cells is determined not only by their phenotype, but also by the microenvironment they inhabit. In particular, accumulating in vitro and in vivo evidence suggests that the interplay between cancer cells and stromal cells can induce mutual phenotype modifications promoting tumour growth and the emergence of resistance to anticancer agents [68–71]. As a first step, we may incorporate an additional structuring variable that stands for the spatial position of cells, and we could include an additional evolution equation for the local density of stromal cells, in order to investigate, in silico, the existence of ecological mechanisms which can foster the spreading of more proliferative and drug resistant phenotypic variants at the interface between solid tumours and host tissues.
Another track to follow to further enrich our model would be to include metabolic determinants of epigenetic dynamics in single cells. Simple phenomenological models have been proposed to describe the influence of oxygen and proton concentration in cancer tissues (see, for instance, [72, 73]). More recently the influence of metabolism on key epigenetic enzymes determining stemness (such as TET1/2, IDH1/2, DNMT3A) has been investigated in detail, setting the focus on DNA methylation dynamics [41, 74]. Mutations of such enzymes have been evidenced in leukemia and preleukemic states [75, 76]. Nevertheless, even without the occurrence of mutations, unequal repartition of these enzymes could be found to be a source of heterogeneity in cancer cell populations making cells diversely sensitive to their metabolic environment. Some cells, heavily loaded in these enzymes, may revert to a stemlike state, yielding germs for drugresistant clones, while the others, not endowed with such abilities, would readily die when exposed to high doses of cytotoxic drugs. In this regard, mathematical modelling is still dependent on more biological knowledge to come about metabolism, stemness and epigenetic dynamics.
Appendix 1. Proofs of Theorem 1 and Theorem 2
The proof of Theorem 1 follows from a more general analysis that we have developed in two recent papers [33, 42], and it uses the results established by the following two lemmas:
Lemma 1
If γ>(β η)^{1/2}, the problem defined by completing (19) with (4)–(5) admits a unique nonnegative nontrivial equilibrium solution \(\overline {n}(x)\) which is given by (11).
Proof of Lemma 1
Lemma 2
Proof of Lemma 2

if γ<(β η)^{1/2}, then g(t)→0 exponentially rapidly;

if γ=(β η)^{1/2}, then g(t) converges to a positive constant;

if γ>(β η)^{1/2}, then g(t)→∞ exponentially rapidly.

if γ<(β η)^{1/2}, then \({\lim \limits _{t \rightarrow \infty } \rho (t) = 0}\);

if γ=(β η)^{1/2}, then \({\lim \limits _{t \rightarrow \infty } \rho (t) = 0}\);

if γ>(β η)^{1/2}, then \({\lim \limits _{t \rightarrow \infty } \rho (t) = \frac {1}{d}\left [ \gamma  (\beta \eta)^{1/2} \right ]}\).
This concludes the proof of Lemma 2. □
 (i)if c(·)=0 and γ−(β η)^{1/2}≤0, then$$ \rho(t) \rightarrow 0, \qquad \text{as }\, t \rightarrow \infty; $$(24)
 (ii)if c(·)=0 and γ−(β η)^{1/2}>0, thenand$$\rho(t) \rightarrow \overline{\rho} = \frac{1}{d}\left[ \gamma(\beta\eta)^{1/2} \right], \qquad \text{as }\, t \rightarrow \infty $$$$\overline{n}(x) = \overline{\rho} \; \frac{{(\eta/\beta)^{1/4}}}{(2\pi)^{1/2}} \exp\left[\frac{1}{2}\left(\frac{\eta}{\beta}\right)^{1/2} x^{2}\right]. $$
This establishes the claims of Theorem 1.
Appendix 2: Proof of Theorem 2
Since \(x \in \mathbb {R}\), there is no loss of generality in translating coordinates so that \(\overline {x}_{c}=0\). Hence, to adapt the method of proof of Theorem 1 to prove Theorem 2 is purely technical. For this reason, we leave Theorem 2 without proof.
Reviewers’ comments
We thank the Reviewers for their comments, all of which are addressed below. Quotations from the Reviewers’ reports are italicised. It was apparent from the comments that some matters required clearer explanation, additional results or greater emphasis, so we have amended the manuscript appropriately.
Reviewer 1  Angela Pisco
In the present paper Lorenzi and coauthors offer a sound theoretical framework to address a critical point on development of drug resistance following treatment. The authors are able to numerically replicate the problem of cell state switching within cancer cell populations composed of cells with different sensitivities to drug. It is now becoming established that cancer treatment is a double edge sword, while the majority of cells die following chemo/radiotherapy, the surviving cells are no innocent bystanders and lead to a more aggressive tumour, mostly composed of cells with a stemcell like phenotype that are multidrug resistant. The authors’ original PDE model is able to replicate published experimental results taking into consideration both nongenetic and environmental conditions. Lorenzi et al. model simulations lead to import conclusions, namely the mathematical demonstration that higher drug doses promote resistant phenotypes and less heterogeneity within cancer cell populations. The entire work is novel and valuable for the community and because of that I’d endorse this paper for publication with minor changes. While I agree that the presented model is general enough for the conclusions to be valid in a panoply of cancers other than leukaemia, I’d like to inquire whether it is feasible with this model to replicate the cycle of sensitivity  resistance  sensitivity... in line with what was described by Sun et al. [Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma, Nature, 2014].
Authors’ response: We thank the Reviewer for this question. To address the Reviewer’s question, we have performed new numerical simulations considering piecewisecontinuous periodic delivery of the cytotoxic drug. The results obtained are summarised by the movie ‘Additional file 2 ’ and are discussed at point R9 in the revised manuscript. In agreement with the experimental results presented by Sun et al., these results clearly show that administering the cytotoxic drug in an alternate fashion leads to the emergence of cycling subpopulations of drugresistant and drugsensitive cells.
All minor issues pointed out by the Reviewer have been addressed.
Reviewer 2  Sébastien Benzekry
In their manuscript, Lorenzi et al. addressed, from a theoretical perspective, the fundamental issue of drug resistance in cancer cell populations. The article is well written and based on solid biological literature. The authors derived, mathematically analysed and simulated a phenotypestructured PDE model that essentializes key aspects of the problem, including the balance between level of resistance to the drug assault and proliferative rate. This is set in the context of adaptive dynamics driven by inheritable epigenetic changes. In doing so, they add another study to several works of them using the same methodology, with sometimes minor differences among them. Here, one interesting result obtained by the authors is that, depending on the dose of a cytotoxic drug delivered to the tumour, the average phenotypical trait toward which the population concentrates (a fact that is rigorously proven) is not always the same. This result is nontrivial and relevant since it demonstrates from basic and minimal biological hypotheses that the dosing has an impact on the phenotypic distribution of a cancer cell population, a topic with increasingly recognised importance for the treatment of cancers. However, no directly applicable recommendation can be derived for the clinical use of cytotoxic agents. I am not a biologist but I find it debatable that the cells closest to stemness (with x=1) are the ones having the smallest proliferative ability. From my understanding, stem cells could be at the same time more resistant and more proliferatively active.
Authors’ response: We thank the Reviewer for having stressed this point. Following the advice of Reviewer 3, we do not mention stemness anymore in the revised manuscript, as it is unnecessary for our conclusions to hold. Therefore, we state that the phenotypic state x=1 corresponds to the highest level of cytotoxicdrug resistance, without making any reference to stemness.
I don’t understand why functions k and p have to be respectively convex and concave. Wouldn’t it be enough to consider them decreasing/increasing (as functions of the norm of x)?
Authors’ response: This may be an alternative modelling strategy and, from the mathematical perspective, it may be interesting to explore it. However, concavity and convexity assumptions lead naturally to smooth fitness landscapes which are close to the approximate fitness landscapes inferred from experimental data through regression techniques [see, for instance, Otwinowski, J., and Plotkin, J.B. (2014). Inferring fitness landscapes by regression produces biased estimates of epistasis. Proc. Natl. Acad. Sci. USA 111(22), E2301–E2309 and references therein].
I also find it surprising, if not inconsistent, that the proliferation rate p(x) can take negative values, while being defined to be the “proliferation due to the assumed velocity of the cell cycle in the absence of betweencell competition for nutrients, and in the absence of druginduced death”. This appears to me to be the underlying reason of the possibility of extinction of the population (first part of Theorem 1), which is quite surprising and sounds biologically unrealistic, in the absence of treatment.
Authors’ response: We thank the Reviewer for his observation. As stated both in the old version version of the manuscript and in the updated manuscript, the function p(x) “stands for the net proliferation rate of cancer cells in the phenotypic state x”. The sentence quoted by the Reviewer from the old version of manuscript was not pertinent and it has been removed from the updated manuscript.
In Table 1, units of the parameters should be provided, when appropriate. What motivated the choice of K=10^{8} cells (no reference is provided)?
Authors’ response: Units have been included in Table 1, and a reference motivating the choice of the value of the carrying capacity K has been added.
What biological situation is modelled here: an in vitro cell line? in vivo tumours in animal models? a clinical patient tumour?
Authors’ response: We thank the Reviewer for this observation. We have clarified this point. As stated in the updated manuscript, we consider an in vitro culture system.
I appreciate the efforts of the authors to adopt relevant values of the parameters based on the literature. However, the value of γ taken seems particularly high (it gives a doubling time of l o g(2)/g a m m a∗24=3.34 hours, which is much faster than the fastest mammalian cell cycle time [1]). This explains why, in Fig. 1 b, the cell population reaches the carrying capacity so fast, probably much faster than in the biological reality. The authors might want to choose a more meaningful value for the duration of the fittest cancer cells’ cycle duration, such as about 25 h. [1] Steel, G. G. and Lamerton, L. F. (1966). The growth rate of human tumours. Br. J. Cancer, 20(1):74–86
Authors’ response: We thank the Reviewer for this suggestion. Following the Reviewer’s advice, we updated the value of the parameter γ so that the duration of the fittest cancer cells’ cycle duration is about 25 h. Because of this, we updated also the values of the parameters β and η following the reasonings presented in the updated manuscript, and we rerun all simulations. Therefore, all figures in the paper have been updated.
All minor issues pointed out by the Reviewers have been addressed.
Reviewer 3  Heiko Enderling
Lorenzi et al. present a mathematical model of phenotypically structured cancer cell populations, and track the evolution of phenotype heterogeneity in the absence of or under selection pressure of a cytotoxic drug. The model is based on previous literature and extended to study continuous heterogeneity and plasticity. The manuscript is well prepared, the work is coherently presented, and the results are clearly discussed. Most of the results are as one would expect, attributing to careful model development. Some results are intriguing, for example indications that maximum tolerable dose may not be the best longterm strategy for tumour control, and that a metronomic scheme may provide a suitable alternative. While certainly plausible, these scenarios can be readily explored with the model and should be included in the manuscript. In particular, it would be interesting to see the temporal evolution of tradeoffs between tumour volume reduction and selection for resistance in an MTD vs. metronomic setting.
Authors’ response: We thank the Reviewer for this suggestion. To address the Reviewer’s question, we have performed new numerical simulations comparing the administration of highdrug doses separated by drugfree periods with the continuous delivery of relatively lowdrug doses. The results obtained are summarised by Fig. 8 and are discussed at point R10 in the revised manuscript. These results suggest that the first type of protocol causes a drastic reduction in the number of cancer cells, although it fosters an increase in the average level of resistance in the population. On the other hand, the second type of protocol maintains a larger tumour burden characterised by a relatively lower average level of resistance. A more accurate comparison between the efficacy of the two therapeutic approaches would require a careful investigation of the respective adverse effects on healthy cells, which cannot be performed using our model. However, we can envisage a lower druginduced toxicity being associated to the second type of protocols [see, for instance, Gately, S., Kerbel, R. (2001). Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J., 7(5), 427–436]. In the light of this observation, the analytical results of Theorem 2 and the numerical results summarised in Fig. 8 suggest that therapeutic protocols consisting of phases of highdose delivery separated by drugfree periods may not offer the best longterm strategy for tumour control, and that protocols based on the continuous delivery of relatively lowdrug doses may represent a suitable alternative.
My major critique is the discussion of cancer stem cells for treatment resistance. The authors introduce a trade off between proliferation and quiescence opposing a gradient of differentiated and cancer stem cells. While this might be biologically realistic, the developed mathematical model does not reflect a cellular hierarchy. In contrast, in the model as is, a population of nonstem cancer cells would grow infinitely in the absence of an initiating and propagating cancer stem cell – a clear violation of the biological concept. As the presented model, results and discussion are solely dependent and reproducible with a proliferation gradient alone, I recommend the stem cell component to be dropped. The oftenattributed cancer stem cell quiescence may be discussed as further support for applicability of the model at the end of the manuscript.
Authors’ response: We thank the Reviewer for this observation. Following the Reviewer’s advice, we do not make any reference to stemness in the revised manuscript, as it is unnecessary for our conclusions to hold.
Declarations
Acknowledgements
This work was supported in part by the French National Research Agency through the “ANR blanche” project Kibord [ANR13BS010004]. The authors thank the Reviewers for their most helpful and insightful comments on the article.
Authors’ contributions
TL performed mathematical study of the model, carried out data processing, and was involved in interpretation of results and drafting of the manuscript. RC made substantial contributions to interpretation of data and critical revision of the manuscript. JC made substantial contributions to critical revision of the manuscript and coordinated the project. All authors gave final approval for publication. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Authors’ Affiliations
References
 Aktipis CA, Boddy AM, Gatenby RA, Brown JS, Maley CC. Life history tradeoffs in cancer evolution. Nat Rev Cancer. 2013; 13(12):883–92.PubMedPubMed CentralView ArticleGoogle Scholar
 Dexter DL, Kowalski HM, Blazar BA, Fligiel Z, Vogel R, Heppner GH. Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res. 1978; 38(10):3174–81.PubMedGoogle Scholar
 Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012; 481(7381):306–13.PubMedPubMed CentralView ArticleGoogle Scholar
 Korolev KS, Xavier JB, Gore J. Turning ecology and evolution against cancer. Nat Rev Cancer. 2014; 14(5):371–80.PubMedView ArticleGoogle Scholar
 Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer. 2006; 6(12):924–35.PubMedView ArticleGoogle Scholar
 Nowell PC. The clonal evolution of tumor cell populations. Science. 1976; 194(4260):23–8.PubMedView ArticleGoogle Scholar
 Marusyk A, Almendro V, Polyak K. Intratumour heterogeneity: a looking glass for cancer?Nat Rev Cancer. 2012; 12(5):323–34.PubMedView ArticleGoogle Scholar
 Brock A, Chang H, Huang S. Nongenetic heterogeneity—a mutationindependent driving force for the somatic evolution of tumours. Nat Rev Genet. 2009; 10(5):336–42.PubMedView ArticleGoogle Scholar
 Glasspool R, Teodoridis JM, Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer. 2006; 94(8):1087–92.PubMedPubMed CentralView ArticleGoogle Scholar
 Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, Kuperwasser C, Lander ES. Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells. Cell. 2011; 146(4):633–44.PubMedView ArticleGoogle Scholar
 Newman JR, Ghaemmaghami S, Ihmels J, Breslow DK, Noble M, DeRisi JL, Weissman JS. Singlecell proteomic analysis of s. cerevisiae reveals the architecture of biological noise. Nature. 2006; 441(7095):840–6.PubMedView ArticleGoogle Scholar
 Raj A, van Oudenaarden A. Nature, nurture, or chance: stochastic gene expression and its consequences. Cell. 2008; 135(2):216–26.PubMedPubMed CentralView ArticleGoogle Scholar
 Chang HH, Oh PY, Ingber DE, Huang S. Multistable and multistep dynamics in neutrophil differentiation. BMC Cell Biol. 2006; 7(1):11.PubMedPubMed CentralView ArticleGoogle Scholar
 Pisco AO, Brock A, Zhou J, Moor A, Mojtahedi M, Jackson D, Huang S. Nondarwinian dynamics in therapyinduced cancer drug resistance. Nat Commun. 2013; 4:2467.PubMedPubMed CentralView ArticleGoogle Scholar
 Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach MA, et al.A chromatinmediated reversible drugtolerant state in cancer cell subpopulations. Cell. 2010; 141(1):69–80.PubMedPubMed CentralView ArticleGoogle Scholar
 Chisholm RH, Lorenzi T, Clairambault J. Cell population heterogeneity and evolution towards drug resistance in cancer: biological and mathematical assessment, theoretical treatment optimisation. Biochimica et Biophysica Acta (BBA)  General Subjects, in press. 2016.Google Scholar
 Huang S. Genetic and nongenetic instability in tumor progression: link between the fitness landscape and the epigenetic landscape of cancer cells. Cancer Metastasis Rev. 2013; 32(3–4):423–48.PubMedView ArticleGoogle Scholar
 Altrock PM, Liu LL, Michor F. The mathematics of cancer: integrating quantitative models. Nat Rev Cancer. 2015; 15(12):730–45.PubMedView ArticleGoogle Scholar
 Anderson AR, Quaranta V. Integrative mathematical oncology. Nat Rev Cancer. 2008; 8(3):227–34.PubMedView ArticleGoogle Scholar
 Byrne HM. Dissecting cancer through mathematics: from the cell to the animal model. Nat Rev Cancer. 2010; 10(3):221–30.PubMedView ArticleGoogle Scholar
 Davies P, Demetrius L, Tuszynski JA. Cancer as a dynamical phase transition. Theor Biol Med Modell. 2011; 8:30.View ArticleGoogle Scholar
 Enderling H, AJ Chaplain M. Mathematical modeling of tumor growth and treatment. Curr Pharm Des. 2014; 20(30):4934–40.PubMedView ArticleGoogle Scholar
 Enderling H, Rejniak KA. Simulating cancer: computational models in oncology. Front Oncol. 2013; 3:233.PubMedPubMed CentralGoogle Scholar
 Gatenby RA, Maini PK. Mathematical oncology: cancer summed up. Nature. 2003; 421(6921):321.PubMedView ArticleGoogle Scholar
 Powathil GG, Swat M, Chaplain MA. Systems oncology: Towards patientspecific treatment regimes informed by multiscale mathematical modelling. Semin Cancer Biol. 2015; 30:13–20.PubMedView ArticleGoogle Scholar
 Stiehl T, Baran N, Ho AD, MarciniakCzochra A. Cell division patterns in acute myeloid leukemia stemlike cells determine clinical course: a model to predict patient survival. Cancer Res. 2015; 75(6):940–9.PubMedView ArticleGoogle Scholar
 Tuszynski JA, Winter P, White D, Tseng CY, Sahu KK, Gentile F, Spasevska I, Omar SI, Nayebi N, Churchill CD, et al.Mathematical and computational modeling in biology at multiple scales. Theor Biol Med Modell. 2014; 11(1):52.View ArticleGoogle Scholar
 Thomas F, Fisher D, Fort P, Marie JP, Daoust S, Roche B, Grunau C, Cosseau C, Mitta G, Baghdiguian S, et al.Applying ecological and evolutionary theory to cancer: a long and winding road. Evol Appl. 2013; 6(1):1–10.PubMedView ArticleGoogle Scholar
 Perthame B. Transport Equations in Biology. Basel: Birkhäuser; 2006.Google Scholar
 Perthame B. Parabolic Equations in Biology. BerlinHeidelberg: Springer; 2015.View ArticleGoogle Scholar
 Champagnat N, Ferrière R, Ben Arous G. The canonical equation of adaptive dynamics: a mathematical view. Selection. 2002; 2(1–2):73–83.View ArticleGoogle Scholar
 Champagnat N, Ferrière R, Méléard S. Unifying evolutionary dynamics: from individual stochastic processes to macroscopic models. Theor Popul Biol. 2006; 69(3):297–321.PubMedView ArticleGoogle Scholar
 Chisholm RH, Lorenzi T, Desvillettes L, Hughes BD. Evolutionary dynamics of phenotypestructured populations: from individuallevel mechanisms to populationlevel consequences. Z Angew Math Phys. 2016; 67(4):1–34.View ArticleGoogle Scholar
 Clairambault J. Can theorems help treat cancer?J Math Biol. 2012; 66(7):1555–8.PubMedView ArticleGoogle Scholar
 Lorz A, Lorenzi T, Hochberg ME, Clairambault J, Perthame B. Populational adaptive evolution, chemotherapeutic resistance and multiple anticancer therapies. ESAIM: Math Modell Numer Anal. 2013; 47(02):377–99.View ArticleGoogle Scholar
 Lorz A, Lorenzi T, Clairambault J, Escargueil A, Perthame B. Modeling the effects of space structure and combination therapies on phenotypic heterogeneity and drug resistance in solid tumors. Bull Math Biol. 2015; 77(1):1–22.PubMedView ArticleGoogle Scholar
 Chisholm RH, Lorenzi T, Lorz A, Larsen AK, De Almeida LN, Escargueil A, Clairambault J. Emergence of drug tolerance in cancer cell populations: An evolutionary outcome of selection, nongenetic instability, and stressinduced adaptation. Cancer Res. 2015; 75(6):930–9.PubMedView ArticleGoogle Scholar
 Pisco A, Huang S. Nongenetic cancer cell plasticity and therapyinduced stemness in tumour relapse:‘what does not kill me strengthens me’. Br J Cancer. 2015; 112(11):1725–32.PubMedPubMed CentralView ArticleGoogle Scholar
 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646–74.PubMedView ArticleGoogle Scholar
 Medema JP. Cancer stem cells: the challenges ahead. Nat Cell Biol. 2013; 15(4):338–44.PubMedView ArticleGoogle Scholar
 Menendez JA, Alarcón T. Metabostemness: A new cancer hallmark. Front Oncol. 2014; 4:121–262.View ArticleGoogle Scholar
 Lorenzi T, Chisholm RH, Desvillettes L, Hughes BD. Dissecting the dynamics of epigenetic changes in phenotypestructured populations exposed to fluctuating environments. J Theor Biol. 2015; 386:166–76.View ArticlePubMedGoogle Scholar
 Chisholm RH, Lorenzi T, Lorz A. Effects of an advection term in nonlocal lotkavolterra equations. Commun Math Sci. 2016; 14:1181–8.View ArticleGoogle Scholar
 Becker C, Hagmann J, Müller J, Koenig D, Stegle O, Borgwardt K, Weigel D. Spontaneous epigenetic variation in the arabidopsis thaliana methylome. Nature. 2011; 480:245–9.PubMedView ArticleGoogle Scholar
 Navin NE. Cancer genomics: one cell at a time. Genome Biol. 2014; 15(8):452.PubMedPubMed CentralView ArticleGoogle Scholar
 LeVeque RJ, Vol. 98. Finite Difference Methods for Ordinary and Partial Differential Equations: Steadystate and Timedependent Problems. Philadelphia: Society for Industrial and Applied Mathematics (SIAM); 2007.View ArticleGoogle Scholar
 Steel G, Lamerton L. The growth rate of human tumours. Br J Cancer. 1966; 20(1):74.PubMedPubMed CentralView ArticleGoogle Scholar
 Bozic I, Reiter JG, Allen B, Antal T, Chatterjee K, Shah P, Moon YS, Yaqubie A, Kelly N, Le DT, et al.Evolutionary dynamics of cancer in response to targeted combination therapy. Elife. 2013; 2:00747.View ArticleGoogle Scholar
 Bozic I, Allen B, Nowak MA. Dynamics of targeted cancer therapy. Trends Mol Med. 2012; 18(6):311–6.PubMedPubMed CentralView ArticleGoogle Scholar
 Gately S, Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J. 2001; 7(5):427–36.PubMedGoogle Scholar
 Cohen AA, GevaZatorsky N, Eden E, FrenkelMorgenstern M, Issaeva I, Sigal A, Milo R, CohenSaidon C, Liron Y, Kam Z, et al.Dynamic proteomics of individual cancer cells in response to a drug. Science. 2008; 322(5907):1511–6.PubMedView ArticleGoogle Scholar
 Delitala M, Lorenzi T. A mathematical model for the dynamics of cancer hepatocytes under therapeutic actions. J Theor Biol. 2012; 297:88–102.PubMedView ArticleGoogle Scholar
 Delitala M, Lorenzi T. A mathematical model for progression and heterogeneity in colorectal cancer dynamics. Theor Popul Biol. 2011; 79(4):130–8.PubMedView ArticleGoogle Scholar
 Jänne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to smallmolecule kinase inhibitors. Nat Rev Drug Discov. 2009; 8(9):709–23.PubMedView ArticleGoogle Scholar
 Lavi O, Greene JM, Levy D, Gottesman MM. The role of cell density and intratumoral heterogeneity in multidrug resistance. Cancer Res. 2013; 73(24):7168–75.PubMedPubMed CentralView ArticleGoogle Scholar
 Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK. Nongenetic origins of celltocell variability in trailinduced apoptosis. Nature. 2009; 459(7245):428–32.PubMedPubMed CentralView ArticleGoogle Scholar
 De Bruin EC, Taylor TB, Swanton C. Intratumor heterogeneity: lessons from microbial evolution and clinical implications. Genome Med. 2013; 5(11):101.PubMedPubMed CentralView ArticleGoogle Scholar
 Acar M, Mettetal JT, van Oudenaarden A. Stochastic switching as a survival strategy in fluctuating environments. Nat Genet. 2008; 40(4):471–5.PubMedView ArticleGoogle Scholar
 Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al.Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Eng J Med. 2012; 366(10):883–92.View ArticleGoogle Scholar
 Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006; 6(8):583–92.PubMedView ArticleGoogle Scholar
 Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Nat Cancer Inst. 2007; 99(19):1441–54.PubMedView ArticleGoogle Scholar
 Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, et al.Reversible and adaptive resistance to braf (v600e) inhibition in melanoma. Nature. 2014; 508(7494):118–22.PubMedView ArticleGoogle Scholar
 André N, Carré M, Pasquier E. Metronomics: towards personalized chemotherapy?Nat Rev Clin Oncol. 2014; 11(7):413–31.PubMedView ArticleGoogle Scholar
 Benzekry S, Pasquier E, Barbolosi D, Lacarelle B, Barlési F, André N, Ciccolini J. Metronomic reloaded: theoretical models bringing chemotherapy into the era of precision medicine: 2015. p 53–61.Google Scholar
 Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Investig. 2000; 105(8):1045–7.PubMedPubMed CentralView ArticleGoogle Scholar
 Scharovsky OG, Mainetti LE, Rozados VR. Metronomic chemotherapy: changing the paradigm that more is better. Curr Oncol. 2009; 16(2):7–15.PubMedPubMed CentralView ArticleGoogle Scholar
 Gatenby RA, Silva AS, Gillies RJ, Frieden BR. Adaptive therapy. Cancer Res. 2009; 69(11):4894–903.PubMedPubMed CentralView ArticleGoogle Scholar
 Bremnes RM, Dønnem T, AlSaad S, AlShibli K, Andersen S, Sirera R, Camps C, Marinez I, Busund LT. The role of tumor stroma in cancer progression and prognosis: emphasis on carcinomaassociated fibroblasts and nonsmall cell lung cancer. J Thoracic Oncol. 2011; 6(1):209–17.View ArticleGoogle Scholar
 Cirri P, Chiarugi P. Cancerassociatedfibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev. 2012; 31(1–2):195–208.PubMedView ArticleGoogle Scholar
 Mao Y, Keller ET, Garfield DH, Shen K, Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev. 2013; 32(1–2):303–15.PubMedPubMed CentralView ArticleGoogle Scholar
 Nieman KM, Kenny HA, Penicka CV, Ladanyi A, BuellGutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, et al.Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011; 17(11):1498–503.PubMedPubMed CentralView ArticleGoogle Scholar
 MendozaJuez B, MartínezGonzález A, Calvo GF, PérezGarcía VM. A mathematical model for the glucoselactate metabolism of in vitro cancer cells. Bull Math Biol. 2011; 74(5):1125–42.PubMedView ArticleGoogle Scholar
 Smallbone K, Gatenby RA, Gillies RJ, Maini PK, Gavaghan DJ. Metabolic changes during carcinogenesis: Potential impact on invasiveness. J Theor Biol. 2007; 244(4):703–13.PubMedView ArticleGoogle Scholar
 Goding CR, Pei D, Lu X. Cancer: pathological nuclear reprogramming?Nat Rev Cancer. 2014; 14(8):568–73.PubMedView ArticleGoogle Scholar
 Delhommeau F, Dupont S, Della Valle V, et al.Mutation in TET2 in myeloid cancers. N Eng J Med. 2009; 360(22):2289–301.View ArticleGoogle Scholar
 Solary E, Bernard OA, Tefferi A, Fuks F, Vainchenker W. The teneleven translocation2 (tet2) gene in hematopoiesis and hematopoietic diseases. Leukemia. 2013; 28(3):485–96.PubMedView ArticleGoogle Scholar
 Miller J. Parabolic cylinder functions. In: Handbook of Mathematical Functions. Washington, DC: U.S. Government Printing Office: 1964. p. 686–720.Google Scholar
 Temme NM. Parabolic cylinder functions In: Olver FWJ, Lozier DW, Boisvert RF, Clark CW, editors. NIST Handbook of Mathematical Functions, Ch. 12. Cambridge University Press: 2010.Google Scholar